Pfizer gets early FTC clearance for Metsera acquisition
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/15/2026
- US stock futures rise on Iran deal optimism; oil tumbles
- Fox to acquire Roku for $22 billion to create streaming and live content giant
- SpaceX extends gains premarket after biggest IPO ever values it at $2.1 trillion
- These 2 space stocks were upgraded at KeyBanc today
- Morgan Stanley outlines sectors set to benefit from market broadening
- This company's long-term growth remains underappreciated: Wolfe
- This stock is the biggest winner from higher voltages in the Datacenter IT room
- Johnson & Johnson shows positive results for TALVEY-DARZALEX drug combination
- Lilly's Jaypirca reduces disease progression risk by 45% in CLL study
- Why does Barclays say it’s time to buy this Spanish stock?
Novo Nordisk earnings preview: Barclays and BofA weigh in
November 4, 2025 4:00 PM ESTBarclays and Bank of America both expect Novo Nordisk's (NYSE: NVO) third-quarter results on November 5 to come broadly in line with expectations but warn the drugmaker could lower the upper end of its 2025 guidance as prescription trends soften.
Barclays analyst Yihan Li said the bank now models +10.9% FY25 topline CER growth (generally in-line with guidance... More
Pfizer earnings preview: Leerink trims estimates
November 3, 2025 4:00 PM ESTPfizer (NYSE: PFE) is set to report third-quarter results on Nov. 4, with analysts at Leerink Partners lowering earnings forecasts ahead of the release.
Leerink reduced its third-quarter earnings-per-share estimate by $0.10, or 13%, to $0.70, and full-year 2025 EPS by 3% to $3.04, within company guidance ($2.90$3.10).
The firm said it cut its 2025 Paxlovid... More
